As of May, 18 AstraZeneca PLC (AZN) Analysts See $0.28 EPS

May 17, 2018 - By Sonya McDaniel

AstraZeneca PLC (NYSE:AZN) Corporate Logo

Earnings report for AstraZeneca PLC (NYSE:AZN) is anticipated on May, 18 before the open., according to Zacks. EPS of $0.28 is 71.72 % down from 2017’s $0.99 EPS. AZN’s profit could reach $697.23M with 32.59 P/E in case $0.28 EPS is published. -78.46 % negative EPS growth is what Wall Street’s sees after $1.30 reported EPS last quarter. Ticker’s shares touched $36.5 during the last trading session after 0.72% change.AstraZeneca PLC has volume of 3.44M shares. Since May 17, 2017 AZN has risen 9.03% and is uptrending. AZN underperformed by 2.52% the S&P 500.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

A total of 5 analysts rate AstraZeneca (NYSE:AZN) as follows: 4 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 80% are bullish. The firm has $42.0 highest and $36.0 lowest target. The avg target $40 is 9.59% above the last ($36.5) price. (NYSE:AZN) has 6 ratings reports on May 17, 2018 according to StockzIntelligence. On Friday, December 29 the firm earned “Buy” rating by J.P. Morgan. On Monday, February 5 Bernstein maintained AstraZeneca PLC (NYSE:AZN) rating. Bernstein has “Buy” rating and $42.0 target. In Friday, December 29 report JP Morgan upgraded the stock to “Overweight” rating. On Thursday, January 18 Leerink Swann maintained AstraZeneca PLC (NYSE:AZN) with “Hold” rating. The company rating was upgraded by Jefferies on Monday, March 19. On Tuesday, February 6 Leerink Swann maintained AstraZeneca PLC (NYSE:AZN) rating. Leerink Swann has “Market Perform” rating and $38 target.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.The firm is worth $90.89 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.30.8 is the P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

A couple more AstraZeneca PLC (NYSE:AZN) news were announced by: which released on April 20, 2018 “AstraZeneca Shares Are Looking Very Weak Right Now”, also on May 15, 2018 announced “AstraZeneca (AZN) PT Raised to $41 at BMO Capital”, the next is “3 Dividend Stocks to Fund Your Nest Egg” on May 16, 2018. has article titled “AstraZeneca (AZN) Said to Weigh Sale of US Rights to Crestor, Could Fetch Over $1 Billion – Bloomberg”.

AstraZeneca PLC (NYSE:AZN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: